Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H12N4 |
| Molecular Weight | 272.304 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1=CN(C=N1)C2=CC=C3N=C(N=CC3=C2)C4=CC=CC=C4
InChI
InChIKey=CSZGXYBGYFNSCO-UHFFFAOYSA-N
InChI=1S/C17H12N4/c1-2-4-13(5-3-1)17-19-11-14-10-15(6-7-16(14)20-17)21-9-8-18-12-21/h1-12H
| Molecular Formula | C17H12N4 |
| Molecular Weight | 272.304 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:52:36 GMT 2025
by
admin
on
Tue Apr 01 16:52:36 GMT 2025
|
| Record UNII |
W9SQ1X2NPZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID301274308
Created by
admin on Tue Apr 01 16:52:36 GMT 2025 , Edited by admin on Tue Apr 01 16:52:36 GMT 2025
|
PRIMARY | |||
|
W9SQ1X2NPZ
Created by
admin on Tue Apr 01 16:52:36 GMT 2025 , Edited by admin on Tue Apr 01 16:52:36 GMT 2025
|
PRIMARY | |||
|
1004997-71-0
Created by
admin on Tue Apr 01 16:52:36 GMT 2025 , Edited by admin on Tue Apr 01 16:52:36 GMT 2025
|
PRIMARY | |||
|
300000023305
Created by
admin on Tue Apr 01 16:52:36 GMT 2025 , Edited by admin on Tue Apr 01 16:52:36 GMT 2025
|
PRIMARY | |||
|
CR-4056
Created by
admin on Tue Apr 01 16:52:36 GMT 2025 , Edited by admin on Tue Apr 01 16:52:36 GMT 2025
|
PRIMARY | |||
|
24898732
Created by
admin on Tue Apr 01 16:52:36 GMT 2025 , Edited by admin on Tue Apr 01 16:52:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Rottapharm Madaus; Class: Analgesic, Imidazoline, Small molecule; Mechanism of Action: Imidazoline I2 receptor agonist; Highest Development Phases: Phase II for Pain, Preclinical for Acute pain, Cancer pain, Neuropathic pain; Most Recent Event: 28 Aug 2015 Phase-II clinical trials in Pain (In the elderly, In adults) in Poland (PO) (EudraCT2015-001136-37)
|
